New research published in ACR Open Rheumatology suggests that modern antidiabetic medications—specifically DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT-2 inhibitors—may carry different risks for developing autoimmune conditions. A study led by Jeffrey A. Sparks, MD, MMSc, of Harvard Medical School and Brigham and Women’s Hospital analyzed hundreds of thousands of patient records, finding significant variations in new-onset autoimmune diagnoses between these drug classes, though no single class was definitively linked to a universal increase in risk.
Comparing Autoimmune Risks Across Drug Classes
The study, which utilized the TriNetX medical records database, compared three major classes of diabetes drugs. Researchers focused on 19 autoimmune conditions, including rheumatoid arthritis, lupus, and psoriasis, to determine if starting these medications correlated with new diagnoses.
According to the findings, DPP-4 inhibitors showed a distinct profile when compared to GLP-1 receptor agonists. Users of DPP-4 inhibitors faced a lower risk for plaque psoriasis, psoriatic arthritis, and autoimmune thyroiditis. Conversely, the same cohort showed a higher risk for bullous pemphigoid and dermatomyositis compared to those on GLP-1 agonists.
The researchers used “target trial emulation” to match over 100,000 pairs of patients for each drug comparison, ensuring the data accounted for variables like BMI, renal function, and HbA1c levels.
Safety Signals and Clinical Interpretation
While the data reveals statistical associations, the authors emphasize that these results do not prove the drugs cause autoimmune diseases. Sparks and his colleagues frame the findings as “preliminary signals” meant to guide future mechanistic research. The study did not include a control group of untreated patients, focusing instead on relative differences between the medication classes.
To validate their methodology, the team examined “negative controls”—diagnoses such as hand lacerations or inguinal hernias—which have no biological link to diabetes treatments. As expected, there were no differences in these rates between drug classes, suggesting the observed autoimmune variations warrant closer inspection.
SGLT-2 Inhibitors vs. GLP-1 Agonists
One of the most notable findings is the lack of variance between GLP-1 agonists and SGLT-2 inhibitors. When these two classes were compared, the study found no significant differences in the risk for any of the 19 autoimmune conditions examined. This suggests a potential stability in autoimmune risk profiles between these two widely prescribed classes of diabetes medications.
Pro Tip: Understanding Relative Risk
When reviewing drug safety data, always distinguish between “relative risk” and “absolute risk.” This study highlights how one drug compares to another, rather than the total likelihood of an individual developing a condition, which remains relatively low for most patients.
Frequently Asked Questions
Does this study prove that diabetes drugs cause autoimmune diseases?
No. According to Sparks and his team, the study identifies “preliminary signals” and statistical associations rather than establishing a direct, causal mechanism.
Were there any autoimmune diseases that showed no difference between drugs?
Yes. For conditions such as rheumatoid arthritis, lupus, inflammatory bowel disease, multiple sclerosis, and celiac disease, the researchers observed no significant differences between any of the medication classes.
Why were DPP-4 inhibitors different from the other classes?
The study notes that DPP-4 inhibitors may block inflammatory processes in the thyroid, which could explain the lower risk for autoimmune thyroiditis. However, the exact reasons for the higher rates of bullous pemphigoid and dermatomyositis remain subjects for future, more targeted research.
Are you a healthcare provider or patient interested in the latest clinical research? Subscribe to our newsletter for updates on how new medical data is shaping treatment protocols.
Keep reading
